

Regulatory Effect of Spray-Dried *Lactiplantibacillus* plantarum K79 on the Activation of Vasodilatory Factors and Inflammatory Responses

Ki Hwan Kim¹, Yongjin Hwang², and Seok-Seong Kang^{1,*}

- ¹Department of Food Science and Biotechnology, College of Life Science and Biotechnology, Dongguk University, Goyang 10326, Korea
- ²Novalacto Co., Ltd., Daejeon 34016, Korea



Received November 14, 2023 Revised November 29, 2023 Accepted November 30, 2023

*Corresponding author: Seok-Seong Kang Department of Food Science and Biotechnology, College of Life Science and Biotechnology, Dongguk University, Goyang 10326, Korea

Tel: +82-31-961-5150 Fax: +82-31-961-5108 E-mail: sskang@dgu.ac.kr

*ORCID

Ki Hwan Kim https://orcid.org/0000-0003-0711-2120 Yongjin Hwang https://orcid.org/0009-0001-3168-8587 Seok-Seong Kang https://orcid.org/0000-0001-7029-9122 **Abstract** The reduction of nitric oxide (NO) bioavailability in the endothelium induces endothelial dysfunction, contributing to the development of hypertension. Although Lactobacillus consumption decreases blood pressure, intracellular signaling pathways related to hypertension have not been well elucidated. Thus, this study examined the effect of spray-dried Lactiplantibacillus plantarum K79 (LpK79) on NO production, intracellular signaling pathways, and inflammatory responses related to vascular function and hypertension. NO production was assessed in human umbilical vein endothelial cells (HUVECs) treated with LpK79. Endothelial NO synthase (eNOS) and intracellular signaling molecules were determined using Western blot analysis. LpK79 dose-dependently increased NO production and activated eNOS via the phosphoinositide 3-kinase/Akt signaling pathway HUVECs. Moreover, LpK79 mitigated the activation of crucial factors pivotal for vascular contraction in smooth muscle cells, such as phospholipase Cγ, myosin phosphatase target subunit 1, and Rho-associated kinase 2. When HUVECs were treated with LpL79 in the presence of Escherichia coli lipopolysaccharide (LPS), LpK79 effectively suppressed mRNA and protein expression of pro-inflammatory mediators induced by E. coli LPS. These results suggest that LpK79 provided a beneficial effect on the regulation of vascular endothelial function.

Keywords Lactiplantibacillus plantarum, hypertension, vascular function, signaling pathway, inflammation

Introduction

Hypertension is strongly associated with substantial cardiovascular disease risks, such as heart attack and stroke (Khalesi et al., 2014). Recent findings revealed that the increasing global prevalence of hypertension is a pressing health concern worldwide, affecting nearly one in two Americans (Ritchey et al., 2018). Furthermore, an estimated 1.3 billion adults are affected by hypertension worldwide (NCD Risk Factor Collaboration, 2021). Nitrovasodilators, such as organic nitrates and sodium nitroprusside, have

proven effective in managing hypertensive crises because nitric oxide (NO) is a vasodilator directly linked to blood pressure regulation (Bryan, 2022). Therefore, NO is pivotal in regulating hypertension, and the reduction of NO bioavailability, otherwise known as endothelial dysfunction, is a characteristic feature of arterial hypertension (Hermann et al., 2006).

Additionally, inadequate NO production impairs blood flow regulation and circulation, subsequently increasing inflammation, oxidative stress, and immune dysfunction (Cervantes-Gracia et al., 2020). Vascular smooth muscle cells (VSMCs), which constitute the vascular wall, are crucial for regulating hypertension due to their plastic and dynamic features (Touyz et al., 2018). Extensive studies have reported that the Rho-associated kinase (ROCK) signaling pathway and its downstream effectors, such as the myosin light chain (MLC), promote inflammation and remodeling in VSMCs, resulting in the pathogenesis of cardiovascular disease (Zhang et al., 2015). Moreover, enhanced ROCK signaling via MLC phosphorylation contributes to VSMC contraction (Ma et al., 2023).

Probiotic lactobacilli, including *Lactiplantibacillus plantarum*, have emerged as a novel therapeutic approach for regulating blood pressure. For instance, *L. plantarum* supplementation significantly reduced blood pressure in hypertensive patients (Sharafedtinov et al., 2013). Additional studies have indicated that probiotic supplementation had positive effects on lowering blood pressure (Dong et al., 2013; He et al., 2017; Khalesi et al., 2014). Malik et al. (2018) demonstrated that *L. plantarum* 299v supplementation improved vascular endothelial function and decreased systemic inflammation in patients with coronary artery disease. Furthermore, conditioned media derived from *L. acidophilus* exhibited anti-apoptotic and anti-inflammatory activities in human umbilical vein endothelial cells (HUVECs) treated with lipopolysaccharide (LPS; Kalani et al., 2016). However, although extensive clinical trials reported positive effects on lowering blood pressure, the cellular mechanism by which probiotic lactobacilli accomplishes this attenuation is not well documented. Thus, this study investigated the impact of spray-dried *L. plantarum* K79 (LpK79) on NO production and elucidated its intracellular signaling pathway in HUVECs. In addition, the signaling pathway in vascular function and hypertension was also examined.

Materials and Methods

Bacterial sample preparation

Spray-dried LpK79 was kindly provided from Novalacto (Daejeon, Korea). Briefly, pasteurized skim milk containing glucose was aseptically inoculated with LpK79 and incubated at 37°C until pH reached 4.2. Next, the bacterial culture was subjected to heat treatment at 85°C for 20 min, cooled at 50°C, and subsequently underwent spray drying.

Nitric oxide production in human umbilical vein endothelial cells

HUVECs were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA) and maintained in Kaighn's modification of Ham's F-12 medium (Gibco, Burlington, ON, Canada) supplemented with 10% fetal bovine serum (Gibco) and antibiotics (HyClone, Logan, UT, USA). The cells were seeded on a 96-well culture plate and treated with various concentrations of LpK79 (0, 2.5, 5, and 10 mg/mL) at 37°C for 24 and 48 h. After obtaining spent culture supernatants, NO production was measured using a nitrate/nitrite fluorometric assay kit (Cayman Chemical, Ann Arbor, MI, USA).

Western blot analysis

HUVECs were seeded onto a 100 mm tissue culture dish and incubated at 37°C for two days. Then, cells were treated with various concentrations of LpK79 (0, 2.5, 5, and 10 mg/mL) at 37°C for 2 h, and cell lysates were obtained using a lysis buffer.

In a separate experiment, VSMCs were purchased from ATCC and maintained in Kaighn's modification of Ham's F-12 medium (Gibco) under culture conditions as previously described. VSMCs were seeded and incubated at 37°C for two days. Afterward, cells were treated with the different concentrations of LpK79 (0, 2.5, 5, and 10 mg/mL) at 37°C for 2 h, and cell lysates were obtained using a lysis buffer to determine ROCK2 and MLC activation. Lysate concentrations were determined using a bicinchonic acid protein assay to perform western blot analysis. Equal volumes of lysate samples were loaded on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, electro-transferred onto polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA), and blocked with 5% skim milk. Next, the membranes were incubated with primary antibodies specific for phosphoinositide 3-kinase (PI3K), phosphorylated PI3K, Akt, phosphorylated Akt, endothelial nitric oxide synthase (eNOS), phosphorylated eNOS, MLC, phosphorylated MLC, ROCK2 (Cell Signaling Technology, Danvers, MA, USA), or β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C. After washing the membranes with Tris-buffered saline containing 0.1% Tween 20, membranes were incubated with horseradish peroxidase-conjugated IgG at room temperature for 2 h. Immunoreactive bands on the membranes were detected using an enhanced chemiluminescence reagent (Dyne Bio, Seongnam, Korea) and visualized with a C-Digit blot scanner (LI-COR Bioscience, Lincoln, NE, USA).

Quantitative reverse transcription polymerase chain reaction

HUVECs were seeded in a 6-well culture plate and incubated at 37°C for two days. The cells were then stimulated with *Escherichia coli* LPS (1 μg/mL) with or without LpK79 (0, 2.5, 5, and 10 mg/mL) at 37°C for 3 h. Total RNA was extracted, and complementary DNA (cDNA) was synthesized using random hexamers and M-MLV reverse transcriptase (Promega, Madison, WI, USA). Pro-inflammatory cytokines, interleukin (IL)-6, and IL-8 genes were amplified through polymerase chain reaction (PCR) using the SYBR green real-time PCR master mix (Toyobo, Osaka, Japan) and a StepOnePlusTM Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) according to the following conditions: initial denaturation at 95°C for 10 min, 40 cycles of denaturation at 95°C for 15 s, and annealing/extension at 60°C for 1 min. The specific primers used in this study were as follows: IL-6, forward 5'-TGCAATAACCACCCCTGACC-3' and reverse 5'-GTGCCCATGCT ACATTTGCC-3'; IL-8, forward 5'-GTGCAGTTTTGCCAAGGAGT-3' and reverse 5'-CTCTGCACCCAGTTTTCCTT-3'; and GAPDH, forward 5'-AAGGTGAAGGTCGGAGTCAA-3' and reverse 5'-ATGACAAGCTTCCCGTTCTC-3'. The relative mRNA expression of IL-6 and IL-8 was normalized to that of GAPDH using the 2^{-ΔΔCT} method.

Enzyme-linked immunosorbent assay

To determine the protein secretion of *E. coli* LPS-stimulated IL-6 and IL-8 in HUVECs with LpK79, HUVECs were seeded as previously described, and cells were stimulated with *E. coli* LPS (1 μg/mL) with or without LpK79 (10 mg/mL) at 37° for 24 h. After obtaining supernatants, IL-6 and IL-8 were quantified using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA).

Statistical analysis

Statistical significance between groups was determined through one-way analysis of variance (ANOVA) using IBM SPSS Statistics 23 software (IBM, Armonk, NY, USA) or unpaired two-tailed t-test using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). p<0.05 was considered statistically significant.

Results and Discussion

Lactiplantibacillus plantarum K79 significantly increases nitric oxide production in human umbilical vein endothelial cells

When HUVECs were incubated with LpK79 at different concentrations (2.5, 5, and 10 mg/mL) for 24 h, LpK79 dose-dependently increased NO production (Fig. 1A). HUVECs were further incubated with LpK79 for 48 h and LpK79 also significantly increased NO production in a dose-dependent manner (Fig. 1B). Previous studies demonstrated that probiotic lactobacilli exert antihypertensive effects in animal models and human clinical trials (Gómez-Guzmán et al., 2015; Jauhiainen et al., 2010; Malik et al., 2018). Our findings corroborate the previous reports that LpK79 promotes NO production in HUVECs, subsequently reducing hypertension. NO released by endothelial cells are critical regulators for vasculature relaxation. Moreover, NO diffused by smooth muscle cells promoted relaxation by increasing cyclic guanosine monophosphate levels (Gu et al., 2020). Although the impact of particular compounds from probiotics on the vascular functions has not been thoroughly explained, a study has demonstrated that short chain fatty acids reduce the blood pressure through G protein-coupled receptor 41, present in vascular endothelial cells (Natarajan et al., 2016). Thus, it may be speculated that metabolic short chain fatty acids derived from probiotics play a role in the regulation of vascular functions.

Lactiplantibacillus plantarum K79 activates endothelial nitric oxide synthase through the phosphoinositide 3-kinase/Akt pathway in human umbilical vein endothelial cells

eNOS primarily facilitated NO production in vascular endothelium. Numerous studies discovered that the phosphatidylinositol 3-kinase (PI3K) pathway triggers the activation of serine-threonine protein kinase B (Akt), leading to the direct phosphorylation of eNOS (Ahmad et al., 2018; Gu et al., 2020). HUVECs were exposed to LpK79 at concentrations of 2.5, 5, and 10 mg/mL for 2 h to investigate the impact of LpK79 on PI3K, Akt, and eNOS phosphorylation. As shown in Fig. 2A,




Fig. 1. Effect of LpK79 on nitric oxide (NO) production in human umbilical vein endothelial cells (HUVECs). HUVECs were incubated with LpK79 (2.5, 5, and 10 mg/mL) at 37°C for 24 h (A) and 48 h (B). NO production was measured using a nitrate/nitrite fluorometric assay kit. p<0.05 was considered statistically significant. ^{a-d} Different letters indicate statistical differences between groups. LpK79, *Lactiplantibacillus plantarum* K79.




Fig. 2. Effect of LpK79 on PI3K/Akt phosphorylation in human umbilical vein endothelial cells (HUVECs) and MYPT1, PLCy, and ROCK2 activation in vascular smooth muscle cells (VSMCs). HUVECs and VSMCs were incubated with LpK79 (2.5, 5, and 10 mg/mL) at 37°C for 2 h. PI3K and Akt phosphorylation in HUVECs (A), MYPT1 and PLCγ phosphorylation, and ROCK2 expression in VSMCs (B) were measured using Western blot analysis. p<0.05 was considered statistically significant. ^{a-c} Different letters indicate statistical differences between groups. LpK79, Lactiplantibacillus plantarum K79; PI3K, phosphoinositide 3-kinase; eNOS, endothelial nitric oxide synthase; PLCγ, phospholipase Cγ; MYPT-1, myosin phosphatase target subunit 1; ROCK2, Rho-associated kinase 2.

LpK79 significantly enhanced PI3K phosphorylation at 5 and 10 mg/mL and Akt phosphorylation at 2.5, 5, and 10 mg/mL. Furthermore, eNOS phosphorylation increased in the presence of LpK79. A recent report determined that while the probiotic *Bifidobacterium longum* ZL0210 did not substantially affect PI3K phosphorylation, it significantly upregulated Akt and eNOS phosphorylation in cardiomyocytes (Qi et al., 2023). Additional studies found that the PI3K/Akt pathway is closely linked to various diseases, including metabolic syndrome, gastrointestinal disorders, and allergies. Probiotic lactobacilli, such as *L. rhamnosus* GG, have been shown to modulate the PI3K/Akt pathway (Mohseni et al., 2021). However, probiotic lactobacilli increasing eNOS phosphorylation via PI3K/Akt pathway activation in human endothelial cells has yet to be established. In this study, we demonstrate that LpK79 activates the PI3K/Akt pathway, directly affecting eNOS activation in HUVECs.

Lactiplantibacillus plantarum K79 decreases factors for vascular smooth muscle cell contraction

In addition to endothelial dysfunction, VSMC contractions contribute to hypertension (Yang and Hori, 2021). The ROCK pathway is crucial, and the myosin phosphatase target subunit (MYPT-1), an essential subset of ROCK targets, participates in VSMC contraction. Additionally, phospholipase Cγ (PLCγ) is integral for promoting VSMC contractions by increasing the intracellular calcium concentration (Touyz et al., 2018). Therefore, PLCγ and MYPT1 phosphorylation and ROCK2 activation in VSMCs were exposed to LpK79 to explore its impact on VSMC contraction. Notably, LpK79 treatment significantly decreased PLCγ and MYPT1 phosphorylation and ROCK2 expression (Fig. 2B). Calcium-independent MLC kinase (MLCK) and calcium-dependent MLC phosphatase (MLCP) pathways regulate MLC phosphorylation in smooth muscle cell contraction. The RhoA/ROCK signaling pathway, a calcium-independent MLCK pathway, activates MYPT1 phosphorylation, prompting MLC activation (Zhao et al., 2021). Additionally, PLC phosphorylation in the calcium-dependent MLCP pathway increases intracellular calcium ions, enhancing MLC phosphorylation and promoting VSMC contraction (Ma et al., 2023). *Lactobacillus fermentum* CECT5716 demonstrated antihypertensive effects in rats with NO synthase inhibition through vasodilation (Gómez-Guzmán et al., 2015). However, the intracellular mechanisms underlying VSMC contraction associated with probiotic lactobacilli remain unclear. Our study indicates that LpK79 is essential for regulating essential factors linked to VSMC contraction.

Lactiplantibacillus plantarum K79 suppresses inflammatory responses in human umbilical vein endothelial cells

Impaired eNOS activation reduces NO production in HUVECs, resulting in endothelial dysfunction, such as inflammation. Thus, we examined whether LpK79 attenuated LPS-induced inflammatory responses in HUVECs. As illustrated in Fig. 3A, *E. coli* LPS augmented IL-6 and IL-8 mRNA expression. In contrast, LpK79 treatment significantly reduced IL-8 mRNA expression but not IL-6 mRNA. However, LpK79 significantly diminished IL-6 secretion in *E. coli* LPS-induced HUVECs and IL-8 secretion. These results suggest that LpK79 suppresses endothelial dysfunction-related inflammatory responses. IL-6 impairs endothelial barrier function and elevates angiotensin II type 1 receptor expression (Wassmann et al., 2004). Angiotensin II is an endocrine ligand that contributes to hypertension by interacting with its angiotensin II type 1 receptor (Eguchi et al., 2018). Therefore, a high IL-6 level in HUVECs has a positive influence on the interaction between angiotensin II and angiotensin II type 1 receptors, increasing hypertension risk. While our observations indicated that IL-6 mRNA expression in HUVECs was not significantly reduced when exposed to LpK79, there was an effective suppression of IL-6 protein levels. This discrepancy may be because mRNA expression was assessed in HUVECs for an extended duration of 24 h. In contrast, IL-8 mRNA and protein levels were significantly suppressed in HUVECs with LpK79 at 24 h. IL-8 is also closely related to the vascular inflammatory process, and excessive IL-8 production was observed in atherosclerotic lesions (Papadopoulou et al., 2008). Thus, inhibiting IL-8 and other inflammatory mediators in activated HUVECs could be beneficial in maintaining endothelial homeostasis and mitigating the risk of vascular diseases.

Conclusion

This study demonstrated that LpK79 increased NO production by activating eNOS through the PI3K/Akt pathway in HUVECs while reducing the expression of factors associated with VSMC contraction. Additionally, LpK79 suppressed inflammatory mediator expressions in HUVECs. These results suggest that LpK79 can provide a beneficial effect on the regulation of vascular endothelial function (Fig. 4).




Fig. 3. The inhibitory effect of LpK79 on IL-6 and IL-8 expression in human umbilical vein endothelial cells (HUVECs). HUVECs were incubated with *Escherichia coli* LPS (1 μ g/mL) with or without LpK79 (10 mg/mL) at 37°C for 24 h. IL-6 (A) and IL-8 mRNA expressions (B) were determined using qRT-PCR. IL-6 (C) and IL-8 (D) protein secretions were measured using ELISA. p<0.05 was considered statistically significant. ^{a-c} Different letters indicate statistical differences between groups. IL, interleukin; LPS, lipopolysaccharide; LpK79, *Lactiplantibacillus plantarum* K79; qRT-PCR, quantitative reverse transcription polymerase chain reaction; ELISA, enzyme-linked immunosorbent assay.




Fig. 4. Schematic illustration of LpK79 regulating factors related to vascular functions in endothelial and smooth muscle cells. LpK79, *Lactiplantibacillus plantarum* K79; LPS, lipopolysaccharide; IL, interleukin; PI3K, phosphoinositide 3-kinase; eNOS, endothelial nitric oxide synthase; PLCγ, phospholipase Cγ; ROCK2, Rho-associated kinase 2; MYPT-1, myosin phosphatase target subunit 1.

Conflicts of Interest

The authors declare no potential conflicts of interest.

Acknowledgements

This work was supported by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) through the Technology Commercialization Support Program, funded by the Ministry of Agriculture, Food and Rural Affairs (MAFRA) (821028-03-2-HD040).

Author Contributions

Conceptualization: Hwang Y, Kang SS. Formal analysis: Kim KH, Kang SS. Methodology: Kim KH, Kang SS. Validation: Kim KH, Hwang Y, Kang SS. Investigation: Kim KH, Kang SS. Writing - original draft: Kim KH, Kang SS. Writing - review & editing: Kim KH, Hwang Y, Kang SS.

Ethics Approval

This article does not require IRB/IACUC approval because there are no human and animal participants.

References

- Ahmad KA, Ze H, Chen J, Khan FU, Xuezhuo C, Xu J, Qilong D. 2018. The protective effects of a novel synthetic β-elemene derivative on human umbilical vein endothelial cells against oxidative stress-induced injury: Involvement of antioxidation and PI3K/Akt/eNOS/NO signaling pathways. Biomed Pharmacother 106:1734-1741.
- Bryan NS. 2022. Nitric oxide deficiency is a primary driver of hypertension. Biochem Pharmacol 206:115325.
- Cervantes-Gracia K, Raja K, Llanas-Cornejo D, Cobley JN, Megson IL, Chahwan R, Husi H. 2020. Oxidative stress and inflammation in the development of cardiovascular disease and contrast induced nephropathy. Vessel Plus 4:27.
- Dong JY, Szeto IMY, Makinen K, Gao Q, Wang J, Qin LQ, Zhao Y. 2013. Effect of probiotic fermented milk on blood pressure: A meta-analysis of randomised controlled trials. Br J Nutr 110:1188-1194.
- Eguchi S, Kawai T, Scalia R, Rizzo V. 2018. Understanding angiotensin II type 1 receptor signaling in vascular pathophysiology. Hypertension 71:804-810.
- Gómez-Guzmán M, Toral M, Romero M, Jiménez R, Galindo P, Sánchez M, Zarzuelo MJ, Olivares M, Gálvez J, Duarte J. 2015. Antihypertensive effects of probiotics *Lactobacillus* strains in spontaneously hypertensive rats. Mol Nutr Food Res 59:2326-2336.
- Gu L, Lian D, Zheng Y, Zhou W, Gu J, Liu X. 2020. Echinacoside-induced nitric oxide production in endothelial cells: Roles of androgen receptor and the PI3K-Akt pathway. Int J Mol Med 45:1195-1202.
- He J, Zhang F, Han Y. 2017. Effect of probiotics on lipid profiles and blood pressure in patients with type 2 diabetes: A meta-analysis of RCTs. Medicine 96:e9166.
- Hermann M, Flammer A, Lüscher TF. 2006. Nitric oxide in hypertension. J Clin Hypertens 8:17-29.
- Jauhiainen T, Rönnback M, Vapaatalo H, Wuolle K, Kautiainen H, Groop PH, Korpela R. 2010. Long-term intervention with

- Lactobacillus helveticus fermented milk reduces augmentation index in hypertensive subjects. Eur J Clin Nutr 64:424-431.
- Kalani M, Hodjati H, Sajedi Khanian M, Doroudchi M. 2016. *Lactobacillus acidophilus* increases the anti-apoptotic micro RNA-21 and decreases the pro-inflammatory micro RNA-155 in the LPS-treated human endothelial cells. Probiotics Antimicrob Proteins 8:61-72.
- Khalesi S, Sun J, Buys N, Jayasinghe R. 2014. Effect of probiotics on blood pressure: A systematic review and meta-analysis of randomized, controlled trials. Hypertension 64:897-903.
- Ma J, Li Y, Yang X, Liu K, Zhang X, Zuo X, Ye R, Wang Z, Shi R, Meng Q. 2023. Signaling pathways in vascular function and hypertension: Molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 8:168.
- Malik M, Suboc TM, Tyagi S, Salzman N, Wang J, Ying R, Tanner MJ, Kakarla M, Baker JE, Widlansky ME. 2018. *Lactobacillus plantarum* 299v supplementation improves vascular endothelial function and reduces inflammatory biomarkers in men with stable coronary artery disease. Circ Res 123:1091-1102.
- Mohseni AH, Casolaro V, Bermúdez-Humarán LG, Keyvani H, Taghinezhad-S S. 2021. Modulation of the PI3K/Akt/mTOR signaling pathway by probiotics as a fruitful target for orchestrating the immune response. Gut Microbes 13:1886844.
- Natarajan N, Hori D, Flavahan S, Steppan J, Flavahan NA, Berkowitz DE, Pluznick JL. 2016. Microbial short chain fatty acid metabolites lower blood pressure via endothelial G protein-coupled receptor 41. Physiol Genomics 48:826-834.
- NCD Risk Factor Collaboration [NCD-RisC]. 2021. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 398:957-980.
- Papadopoulou C, Corrigall V, Taylor PR, Poston RN. 2008. The role of the chemokines MCP-1, GRO-α, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques. Cytokine 43:181-186.
- Qi S, Liu D, Ma B, Yang L, Yu H. 2023. Screening of the most efficacious lactic acid bacteria strain for myocardial infarction recovery and verification and exploration of its functions and mechanisms. Biosci Microbiota Food Health 42:13-23.
- Ritchey MD, Gillespie C, Wozniak G, Shay CM, Thompson-Paul AM, Loustalot F, Hong Y. 2018. Potential need for expanded pharmacologic treatment and lifestyle modification services under the 2017 ACC/AHA hypertension guideline. J Clin Hypertens 20:1377-1391.
- Sharafedtinov KK, Plotnikova OA, Alexeeva RI, Sentsova TB, Songisepp E, Stsepetova J, Smidt I, Mikelsaar M. 2013. Hypocaloric diet supplemented with probiotic cheese improves body mass index and blood pressure indices of obese hypertensive patients: A randomized double-blind placebo-controlled pilot study. Nutr J 12:138.
- Touyz RM, Alves-Lopes R, Rios FJ, Camargo LL, Anagnostopoulou A, Arner A, Montezano AC. 2018. Vascular smooth muscle contraction in hypertension. Cardiovasc Res 114:529-539.
- Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Böhm M, Nickenig G. 2004. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 94:534-541.
- Yang Q, Hori M. 2021. Characterization of contractile machinery of vascular smooth muscles in hypertension. Life 11:702.
- Zhang X, Zhang T, Gao F, Li Q, Shen C, Li Y, Li W, Zhang X. 2015. Fasudil, a Rho-kinase inhibitor, prevents intima-media thickening in a partially ligated carotid artery mouse model: Effects of fasudil in flow-induced vascular remodeling. Mol Med Rep 12:7317-7325.
- Zhao L, Yuan F, Pan N, Yu Y, Yang H, Liu Y, Wang R, Zhang B, Wang G. 2021. CFTR deficiency aggravates Ang II induced vasoconstriction and hypertension by regulating Ca²⁺ influx and RhoA/Rock pathway in VSMCs. Front Biosci 26:1396-1410.